ClinicaliQ Trial Snapshot
- Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting • Phase III • Gastroenterology • NCT03683251.
- Portal Extension Study Summary.
- Implanted drug delivery system releasing ranibizumab shows sustained safety and effectiveness in wet age-related macular degeneration over extended follow-up.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221. Conditions: Neovascular Age-Related Macular Degeneration Interventions: PDS Implant with Ranibizumab 100 mg/mL Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 1000 participants